Viking Therapeutics, Inc.
COMPOSITIONS FOR THE TREATMENT OF FIBROSIS

Abstract:

The present disclosure is directed to methods of treating fibrotic conditions by administration of TR.beta. agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TR.beta. agonists with TGF-.beta.-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.